Silvia Buriolla

407 total citations
17 papers, 210 citations indexed

About

Silvia Buriolla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Silvia Buriolla has authored 17 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Silvia Buriolla's work include Advanced Breast Cancer Therapies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and HER2/EGFR in Cancer Research (4 papers). Silvia Buriolla is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and HER2/EGFR in Cancer Research (4 papers). Silvia Buriolla collaborates with scholars based in Italy, United States and Ukraine. Silvia Buriolla's co-authors include Fabio Puglisi, Mattia Garutti, Giada Targato, Roberta Mazzeo, Alessandro Marco Minisini, Paola Di Nardo, C. Lisanti, Elisa Bertoli, Carla Corvaja and Giacomo Pelizzari and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Silvia Buriolla

14 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silvia Buriolla Italy 6 138 99 57 53 19 17 210
Nisha Unni United States 8 141 1.0× 68 0.7× 65 1.1× 56 1.1× 12 0.6× 28 262
Kuikui Jiang China 9 96 0.7× 51 0.5× 81 1.4× 73 1.4× 16 0.8× 30 227
Isabel Calvo Spain 8 189 1.4× 83 0.8× 110 1.9× 67 1.3× 10 0.5× 18 315
Andrés Aguilar Spain 7 97 0.7× 102 1.0× 120 2.1× 63 1.2× 22 1.2× 17 209
Kepa Amillano Spain 8 103 0.7× 71 0.7× 91 1.6× 116 2.2× 12 0.6× 20 221
A. Seun Ajiboye United States 4 85 0.6× 193 1.9× 170 3.0× 65 1.2× 15 0.8× 6 359
Mark R. Nathan United Kingdom 3 71 0.5× 56 0.6× 93 1.6× 36 0.7× 23 1.2× 5 202
Yizhao Xie China 9 100 0.7× 67 0.7× 46 0.8× 71 1.3× 9 0.5× 31 221
Mathias Tesson United Kingdom 8 79 0.6× 55 0.6× 73 1.3× 65 1.2× 13 0.7× 15 207

Countries citing papers authored by Silvia Buriolla

Since Specialization
Citations

This map shows the geographic impact of Silvia Buriolla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Buriolla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Buriolla more than expected).

Fields of papers citing papers by Silvia Buriolla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Buriolla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Buriolla. The network helps show where Silvia Buriolla may publish in the future.

Co-authorship network of co-authors of Silvia Buriolla

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Buriolla. A scholar is included among the top collaborators of Silvia Buriolla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Buriolla. Silvia Buriolla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Garattini, Silvio Ken, Debora Basile, Vallì De Re, et al.. (2024). The potential of retinoic acid receptors as prognostic biomarkers and therapeutic targets in gastric cancer. Frontiers in Oncology. 14. 1453934–1453934.
2.
Buriolla, Silvia, et al.. (2024). Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion. European Journal of Cancer. 216. 115193–115193. 1 indexed citations
3.
Nardo, Paola Di, Debora Basile, Ana Paula dos Reis Velloso Siciliano, et al.. (2023). Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA). Digestive and Liver Disease. 56(5). 786–794.
4.
Pelizzari, Giacomo, Elisa Bertoli, Silvia Buriolla, et al.. (2023). Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase. Melanoma Research. 33(5). 398–405. 1 indexed citations
5.
Buriolla, Silvia, Giacomo Pelizzari, Carla Corvaja, et al.. (2022). Immunotherapy in NSCLC Patients with Brain Metastases. International Journal of Molecular Sciences. 23(13). 7068–7068. 23 indexed citations
6.
Nardo, Paola Di, C. Lisanti, Mattia Garutti, et al.. (2022). Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. Expert Opinion on Drug Safety. 21(11). 1341–1355. 65 indexed citations
7.
Garutti, Mattia, et al.. (2021). CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. Cells. 10(6). 1334–1334. 46 indexed citations
8.
Basile, Debora, Giada Targato, Marco Alberti, et al.. (2021). 295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi). Annals of Oncology. 32. S493–S493. 3 indexed citations
9.
Michelotti, A., Elisa Sperti, Roberta Mazzeo, et al.. (2021). LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.. Journal of Clinical Oncology. 39(15_suppl). e16102–e16102. 4 indexed citations
10.
Pelizzari, Giacomo, Carla Corvaja, Giada Targato, et al.. (2021). 1312P Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy. Annals of Oncology. 32. S1011–S1011. 1 indexed citations
11.
Garutti, Mattia, Serena Bonin, Silvia Buriolla, et al.. (2021). Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. Cancers. 13(8). 1819–1819. 19 indexed citations
12.
Mazzeo, Roberta, Silvia Buriolla, Alessandra Franzoni, et al.. (2021). Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).. Journal of Clinical Oncology. 39(15_suppl). 1027–1027. 2 indexed citations
13.
Basile, Debora, Lorenzo Gerratana, Carla Corvaja, et al.. (2021). First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. The Breast. 57. 104–112. 22 indexed citations
14.
Garutti, Mattia, Silvia Buriolla, Elisa Bertoli, et al.. (2020). “To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. Cancers. 12(7). 1941–1941. 4 indexed citations
15.
Gerratana, Lorenzo, Debora Basile, Alessandra Franzoni, et al.. (2020). Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology. 10. 18 indexed citations
16.
Basile, Debora, Maurizio Polano, Silvia Buriolla, et al.. (2020). Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study.. Journal of Clinical Oncology. 38(15_suppl). e16118–e16118. 1 indexed citations
17.
Pelizzari, Giacomo, Lorenzo Gerratana, Debora Basile, et al.. (2019). Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. Journal of Clinical Oncology. 37(15_suppl). 577–577.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nisha Unni Breakdown of academic impact, for papers by Kuikui Jiang Breakdown of academic impact, for papers by Isabel Calvo Breakdown of academic impact, for papers by Andrés Aguilar Breakdown of academic impact, for papers by Kepa Amillano Breakdown of academic impact, for papers by A. Seun Ajiboye Breakdown of academic impact, for papers by Mark R. Nathan Breakdown of academic impact, for papers by Yizhao Xie Breakdown of academic impact, for papers by Mathias Tesson
Rankless by CCL
2026